In a major breakthrough in the treatment of Severe Aortic Stenosis,<br />Apollo Hospitals, Chennai, today performed the ...

Background Previous research on congenital aortic stenosis (AS) mainly focused on children, while data on long-term outcomes ...

Abbott wins CE Mark in Europe for expanded Navitor use, boosting its Structural Heart business and lifting ABT stock.

Kini AS, Tang GHL, Yaryura R, Petrossian G, Roberts DK, Rahman A, et al. 1-year real-world outcomes of TAVR with the ...

Over the past several days, the leaders in cardiology convened in Madrid for the European Society of Cardiology (ESC) ...

The European Society of Cardiology (ESC) has updated its care guidelines for valvular heart disease, due in large part to recent trial results from Edwards Lifesciences.

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...

Pulsed field ablation and transcatheter aortic valve implants were in focus at the European Society of Cardiology Congress in ...

Abbott (NYSE: ABT) announced today that it received CE mark for an expanded indication for its Navitor TAVI system.

Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing ...

Calcific aortic valve disease (CAVD) is the most prevalent acquired valve heart disorder in aging populations. Its most ...